Breaking News

US Is About To License Remdesivir To Treat COVID-19

According to US health experts, the drug Remdesivir is able to shorten the recovery time of COVID-19 patients by 31%, so the health industry in the country said that it will soon be approved for use after positive signals.

Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci has just published preliminary results showing that Remdesivir has shortened recovery time of COVID-19 patients by 31%.

Accordingly, people infected with COVID-19 only took 11 days to recover from the disease instead of 15 days.
While the results still take time to assess, Mr. Fauci remains optimistic that it could open the door to treating COVID-19 patients and will soon become the standard treatment.

The Remdesivir trial conducted by the US National Institute of Allergy and Infections randomly controlled 1,060 patients worldwide. In addition, the mortality rate in patients using the drug is lower than the non-user.

The US Food and Drug Administration (FDA) plans to soon allow the use of remdesivir in the treatment of Covid-19 after positive signals.

US President Donald Trump also said this is a positive signal. He wanted the licensing to be carried out soon but to ensure safety.

However, there are still doubts about the effectiveness of the remdesivir antiviral drug produced by the US pharmaceutical company Gilead Sciences. Remdesivir has never been approved as a treatment for any disease. This drug has previously been tested against Ebola but is not effective.

No comments